Avadel Pharmaceuticals (AVDL) Jefferies London Healthcare Conference 2024 summary

Product differentiation and market positioning

• LUMRYZ is the only once-at-bedtime oxybate for narcolepsy, addressing both daytime and nighttime symptoms without requiring patients to wake up for a second dose.

• FDA granted orphan exclusivity for both adults and pediatrics, affirming the benefit of not disrupting sleep architecture.

• The product targets three patient segments: switch (current oxybate users), previously treated/discontinued, and naive (new to oxybate), with a total addressable market of 35,000–40,000 patients.

• Five quarters into launch, LUMRYZ has reached 2,300 patients and is on track for a billion-dollar opportunity with 8,000 reimbursed patients.

• Uptake is strong among early adopters, with increasing penetration into slower adopter segments.

Financial performance and growth trajectory

• Achieved break-even in Q3 with $6 million EBITDA and expects to be cash flow positive in the current quarter.

• Maintains a $200 million run rate, with consistent quarterly patient additions of 700.

• Net revenue per patient is about $100,000 annually when including free drug recipients; pricing for reimbursed patients remains stable.

• Inventory headwinds are due to physical storage limits at specialty pharmacies, causing timing shifts in revenue recognition.

• Guidance for 2025 is under evaluation, with potential pre-announcement at an upcoming broker conference.

Patient mix, uptake, and market expansion

• Demand has been consistent, with a shift toward more naive patients as the launch matures.

• Over 150 new prescribers with no prior oxybate history have written prescriptions, indicating market expansion.

• Growth is driven by both breadth (more prescribers) and depth (existing prescribers writing more), with focus on expanding to slower adopters.

• Pediatric indication recently added, opening a new but smaller patient segment.

• 80–90% of future demand expected from switch and naive segments, with consistent growth in previously treated/discontinued patients.